Dock-and-lock (DNL) vaccines for cancer therapy

A DNL (dock and lock) complex comprising:

• a) an antibody moiety that binds to a dendritic cell antigen selected from the group consisting of CD209 (DC-SIGN), CD34, CD74, CD205, TLR 2 (toll-like receptor 2), TLR 4, TLR 7, TLR 9, BDCA-2, BDCA-3, BDCA-4, and HLA-DR, wherein the antibody moiety is attached to a DDD (dimerization and docking domain) moiety, wherein said DDD moiety has a peptide sequence from a dimerization and docking domain of protein kinase A selected from the group consisting of the amino acid sequence of SEQ ID NO:
• 10 and SEQ ID NO:
• 11;
• and
• b) a xenoantigen moiety attached to an AD (anchor domain) moiety, wherein the AD moiety has a peptide sequence from an anchoring domain of an AKAP (A-kinase anchoring protein) selected from the group consisting of the amino acid sequence of SEQ ID NO:
• 13;
• SEQ ID NO:
• 12;
• SEQ ID NO:
• 19;
• SEQ ID NO:
• 20;
• SEQ ID NO:
• 21;
• SEQ ID NO:
• 22;
• SEQ ID NO:
• 23;
• SEQ ID NO:
• 24;
• SEQ ID NO:
• 25;
• SEQ ID NO:
• 26;
• SEQ ID NO:
• 27 and SEQ ID NO:
• 28;
• wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the DNL complex and wherein the DNL complex induces an immune response in vivo.